COVID -

MMWR Booster for: Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years — United States, August 31–October 23, 2022, Weekly / November 4, 2022 / 71(44);1401–1406

Posted on January 17, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways: Safety Profile Similar to Monovalent Boosters: Early safety findings for bivalent COVID-19 mRNA booster doses in persons aged ≥12 years are consistent with those reported for monovalent

MMWR Booster for: Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022, Weekly / November 11, 2022 / 71(45);1436–1441

Posted on January 15, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Bivalent Booster Recommendation: In fall 2022, the CDC recommended a bivalent mRNA COVID-19 vaccine booster dose for individuals aged 5 years and older, to be administered at

MMWR Booster for: COVID-19–Associated Hospitalizations Among U.S. Infants Aged <6 Months — COVID-NET, 13 States, June 2021–August 2022, Weekly / November 11, 2022 / 71(45);1442–1448

Posted on January 14, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Increased Hospitalization Rates: During the Omicron variant-predominant periods, hospitalization rates among infants aged <6 months increased compared to the Delta variant period, but severe disease indicators among

MMWR Booster for: Perception of Local COVID-19 Transmission and Use of Preventive Behaviors Among Adults with Recent SARS-CoV-2 Infection — Illinois and Michigan, June 1–July 31, 2022, Weekly / November 18, 2022 / 71(46);1471–1478

Posted on January 13, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Perception vs Reality: Half of the surveyed adults in Michigan and Illinois who had recent SARS-CoV-2 infections perceived local COVID-19 transmission as low or moderate, despite high

MMWR Booster for: Sociodemographic Variation in Early Uptake of COVID-19 Vaccine and Parental Intent and Attitudes Toward Vaccination of Children Aged 6 Months–4 Years — United States, July 1–29, 2022, Weekly / November 18, 2022 / 71(46);1479–1484

Posted on January 13, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Low Vaccination Rates Among Young Children: As of July 2022, only 4% of children aged 6 months–4 years had received at least one dose of the COVID-19

MMWR Booster for: SARS-CoV-2 Serology and Self-Reported Infection Among Adults — National Health and Nutrition Examination Survey, United States, August 2021–May 2022, December 2, 2022 / 71(48);1522–1525

Posted on January 11, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways 1. 41.6% of adults had antibodies indicating past SARS-CoV-2 infection during August 2021–May 2022, with 43.7% potentially asymptomatic. 2. Seropositivity without vaccination was more common among younger

MMWR Booster for: Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 — United States, April–September 2022, Weekly / December 2, 2022 / 71(48);1531–1537

Posted on January 10, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Paxlovid, an outpatient antiviral medication, is linked to a 51% reduction in hospitalization rates for COVID-19 among U.S. adults when prescribed within 5 days of diagnosis. This

MMWR Booster for: Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022, Weekly / December 2, 2022 / 71(48);1526–1530

Posted on January 10, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Bivalent Boosters’ Effectiveness: The study reveals that bivalent mRNA COVID-19 boosters offer significant additional protection against symptomatic SARS-CoV-2 infection, especially for those who had 2 to 4

MMWR Booster for: Prevalence of SARS-CoV-2 and Influenza Coinfection and Clinical Characteristics Among Children and Adolescents Aged <18 Years Who Were Hospitalized or Died with Influenza — United States, 2021–22 Influenza Season, Weekly / December 16, 2022 / 71(50);1589–1596

Posted on January 5, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways 6% of pediatric influenza hospitalizations had concurrent SARS-CoV-2 (COVID) coinfection during the 2021–22 influenza season. Coinfected patients exhibited a higher need for respiratory support (invasive or noninvasive)

MMWR Booster for: COVID-19 and Other Underlying Causes of Cancer Deaths — United States, January 2018–July 2022, Weekly / December 16, 2022 / 71(50);1583–1588

Posted on January 5, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways: Increased Risk for Cancer Patients: Individuals with cancer showed an elevated risk of dying from COVID-19, with 2.0% in 2020 and 2.4% in 2021 having COVID-19 as

Epidemiology, Broadly Speaking

Tag: COVID